luthera

  • Asteroid Families Portal

    (918) Itha, (945) Barcelona, (1040) Klumpkea, (1189) Terentia, (1272) Gefion, (1303) Luthera, (1484) Postrema, (1668) Hanna, (1726) Hoffmeister, (1892) Lucienne ...

      Kata Kunci Pencarian:

      lutheran adalahlutheran dan calvinislutheran churchlutheran world federationlutheranismlutheran evangelikallutheran artinyalutheran school of theology at chicagolutheran high churchlutheran tradisionalSearch Results

      Artikel Terkait "luthera"

      GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)

      LUTATHERA is a treatment for SSTR+ GEP-NETs. Learn how LUTATHERA works, what makes LUTATHERA different, and access support. See full Prescribing & Safety Info.

      Lutathera Uses, Side Effects & Warnings - Drugs.com

      30 Apr 2024 · Physician reviewed Lutathera patient information - includes Lutathera description, dosage and directions.

      FDA Approves Lutathera for Neuroendocrine Tumors - NCI

      08 Feb 2018 · FDA has approved Lutathera® for some people with neuroendocrine tumors (NETs) that affect the digestive tract. On January 29, FDA approved Lutathera® for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract, known as GEP-NETs.

      What to Expect with Treatment | LUTATHERA

      Read about how LUTATHERA is given and learn what to expect before, during, and after treatment with LUTATHERA. See full Prescribing and Safety Information.

      About Your Lutathera® Treatment - Memorial Sloan Kettering Cancer Center

      28 Sep 2022 · This information will help you get ready for your Lutathera treatment at Memorial Sloan Kettering (MSK). Lutathera is a type of peptide receptor radionuclide therapy (PRRT).

      GEP-NETs Treatment | LUTATHERA® (lutetium Lu 177 dotatate)

      Access HCP information about LUTATHERA, a treatment for SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs). See full Prescribing and Safety Info.

      FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS

      On January 26, 2018, the Food and Drug Administration approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the ...

      FDA approves new treatment for certain digestive tract cancers

      FDA approves first radioactive drug for a certain type of digestive tract cancer called GEP-NETs

      label - Food and Drug Administration

      LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. (1)

      Lutathera Delays Growth of Advanced Neuroendocrine Tumors

      01 Mar 2024 · Treatment with Lu 177-dotatate (Lutathera) and octreotide (Sandostatin) shrank tumors in people with advanced neuroendocrine tumors, a clinical trial found.